Fluorescence polarization system for rapid COVID-19 diagnosis

Chang Yeol Lee; Ismail Degani; Jiyong Cheong; Jae Hyun Lee; Hyun Jung Choi; Jinwoo Cheon; Hakho Lee

doi:10.1016/j.bios.2021.113049

Fluorescence polarization system for rapid COVID-19 diagnosis

Chang Yeol Lee, Ismail Degani, Jiyong Cheong, Jae Hyun Lee, Hyun Jung Choi, Jinwoo Cheon, Hakho Lee

Research output: Contribution to journal › Article › peer-review

33 Citations (Scopus)

Abstract

Prompt diagnosis, patient isolation, and contact tracing are key measures to contain the coronavirus disease 2019 (COVID-19). Molecular tests are the current gold standard for COVID-19 detection, but are carried out at central laboratories, delaying treatment and control decisions. Here we describe a portable assay system for rapid, onsite COVID-19 diagnosis. Termed CODA (CRISPR Optical Detection of Anisotropy), the method combined isothermal nucleic acid amplification, activation of CRISPR/Cas12a, and signal generation in a single assay, eliminating extra manual steps. Importantly, signal detection was based on the ratiometric measurement of fluorescent anisotropy, which allowed CODA to achieve a high signal-to-noise ratio. For point-of-care operation, we built a compact, standalone CODA device integrating optoelectronics, an embedded heater, and a microcontroller for data processing. The developed system completed SARS-CoV-2 RNA detection within 20 min of sample loading; the limit of detection reached 3 copy/μL. When applied to clinical samples (10 confirmed COVID-19 patients; 10 controls), the rapid CODA test accurately classified COVID-19 status, in concordance with gold-standard clinical diagnostics.

Original language	English
Article number	113049
Journal	Biosensors and Bioelectronics
Volume	178
DOIs	https://doi.org/10.1016/j.bios.2021.113049
Publication status	Published - 2021 Apr 15

Bibliographical note

Funding Information:
This work was supported in part by the the US National Institutes of Health ( R01CA229777 , R21DA049577 , U01CA233360 , R01CA239078 , R01CA237500 ); the US Department of Defense ( W81XWH1910199 , W81XWH1910194 ); MGH Scholar Fund; and the Korea Institute for Basic Science ( IBS-R026-D1 ).

Funding Information:
This work was supported in part by the the US National Institutes of Health (R01CA229777, R21DA049577, U01CA233360, R01CA239078, R01CA237500); the US Department of Defense (W81XWH1910199, W81XWH1910194); MGH Scholar Fund; and the Korea Institute for Basic Science (IBS-R026-D1).

Publisher Copyright:
© 2021 Elsevier B.V.

All Science Journal Classification (ASJC) codes

Biotechnology
Biophysics
Biomedical Engineering
Electrochemistry

Access to Document

10.1016/j.bios.2021.113049

Cite this

@article{260518e838ed418eba85472df61ea66a,

title = "Fluorescence polarization system for rapid COVID-19 diagnosis",

abstract = "Prompt diagnosis, patient isolation, and contact tracing are key measures to contain the coronavirus disease 2019 (COVID-19). Molecular tests are the current gold standard for COVID-19 detection, but are carried out at central laboratories, delaying treatment and control decisions. Here we describe a portable assay system for rapid, onsite COVID-19 diagnosis. Termed CODA (CRISPR Optical Detection of Anisotropy), the method combined isothermal nucleic acid amplification, activation of CRISPR/Cas12a, and signal generation in a single assay, eliminating extra manual steps. Importantly, signal detection was based on the ratiometric measurement of fluorescent anisotropy, which allowed CODA to achieve a high signal-to-noise ratio. For point-of-care operation, we built a compact, standalone CODA device integrating optoelectronics, an embedded heater, and a microcontroller for data processing. The developed system completed SARS-CoV-2 RNA detection within 20 min of sample loading; the limit of detection reached 3 copy/μL. When applied to clinical samples (10 confirmed COVID-19 patients; 10 controls), the rapid CODA test accurately classified COVID-19 status, in concordance with gold-standard clinical diagnostics.",

author = "Lee, {Chang Yeol} and Ismail Degani and Jiyong Cheong and Lee, {Jae Hyun} and Choi, {Hyun Jung} and Jinwoo Cheon and Hakho Lee",

note = "Funding Information: This work was supported in part by the the US National Institutes of Health ( R01CA229777 , R21DA049577 , U01CA233360 , R01CA239078 , R01CA237500 ); the US Department of Defense ( W81XWH1910199 , W81XWH1910194 ); MGH Scholar Fund; and the Korea Institute for Basic Science ( IBS-R026-D1 ). Funding Information: This work was supported in part by the the US National Institutes of Health (R01CA229777, R21DA049577, U01CA233360, R01CA239078, R01CA237500); the US Department of Defense (W81XWH1910199, W81XWH1910194); MGH Scholar Fund; and the Korea Institute for Basic Science (IBS-R026-D1). Publisher Copyright: {\textcopyright} 2021 Elsevier B.V.",

year = "2021",

month = apr,

day = "15",

doi = "10.1016/j.bios.2021.113049",

language = "English",

volume = "178",

journal = "Biosensors and Bioelectronics",

issn = "0956-5663",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Fluorescence polarization system for rapid COVID-19 diagnosis

AU - Lee, Chang Yeol

AU - Degani, Ismail

AU - Cheong, Jiyong

AU - Lee, Jae Hyun

AU - Choi, Hyun Jung

AU - Cheon, Jinwoo

AU - Lee, Hakho

N1 - Funding Information: This work was supported in part by the the US National Institutes of Health ( R01CA229777 , R21DA049577 , U01CA233360 , R01CA239078 , R01CA237500 ); the US Department of Defense ( W81XWH1910199 , W81XWH1910194 ); MGH Scholar Fund; and the Korea Institute for Basic Science ( IBS-R026-D1 ). Funding Information: This work was supported in part by the the US National Institutes of Health (R01CA229777, R21DA049577, U01CA233360, R01CA239078, R01CA237500); the US Department of Defense (W81XWH1910199, W81XWH1910194); MGH Scholar Fund; and the Korea Institute for Basic Science (IBS-R026-D1). Publisher Copyright: © 2021 Elsevier B.V.

PY - 2021/4/15

Y1 - 2021/4/15

N2 - Prompt diagnosis, patient isolation, and contact tracing are key measures to contain the coronavirus disease 2019 (COVID-19). Molecular tests are the current gold standard for COVID-19 detection, but are carried out at central laboratories, delaying treatment and control decisions. Here we describe a portable assay system for rapid, onsite COVID-19 diagnosis. Termed CODA (CRISPR Optical Detection of Anisotropy), the method combined isothermal nucleic acid amplification, activation of CRISPR/Cas12a, and signal generation in a single assay, eliminating extra manual steps. Importantly, signal detection was based on the ratiometric measurement of fluorescent anisotropy, which allowed CODA to achieve a high signal-to-noise ratio. For point-of-care operation, we built a compact, standalone CODA device integrating optoelectronics, an embedded heater, and a microcontroller for data processing. The developed system completed SARS-CoV-2 RNA detection within 20 min of sample loading; the limit of detection reached 3 copy/μL. When applied to clinical samples (10 confirmed COVID-19 patients; 10 controls), the rapid CODA test accurately classified COVID-19 status, in concordance with gold-standard clinical diagnostics.

AB - Prompt diagnosis, patient isolation, and contact tracing are key measures to contain the coronavirus disease 2019 (COVID-19). Molecular tests are the current gold standard for COVID-19 detection, but are carried out at central laboratories, delaying treatment and control decisions. Here we describe a portable assay system for rapid, onsite COVID-19 diagnosis. Termed CODA (CRISPR Optical Detection of Anisotropy), the method combined isothermal nucleic acid amplification, activation of CRISPR/Cas12a, and signal generation in a single assay, eliminating extra manual steps. Importantly, signal detection was based on the ratiometric measurement of fluorescent anisotropy, which allowed CODA to achieve a high signal-to-noise ratio. For point-of-care operation, we built a compact, standalone CODA device integrating optoelectronics, an embedded heater, and a microcontroller for data processing. The developed system completed SARS-CoV-2 RNA detection within 20 min of sample loading; the limit of detection reached 3 copy/μL. When applied to clinical samples (10 confirmed COVID-19 patients; 10 controls), the rapid CODA test accurately classified COVID-19 status, in concordance with gold-standard clinical diagnostics.

UR - http://www.scopus.com/inward/record.url?scp=85100247110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85100247110&partnerID=8YFLogxK

U2 - 10.1016/j.bios.2021.113049

DO - 10.1016/j.bios.2021.113049

M3 - Article

C2 - 33540323

AN - SCOPUS:85100247110

SN - 0956-5663

VL - 178

JO - Biosensors and Bioelectronics

JF - Biosensors and Bioelectronics

M1 - 113049

ER -

Fluorescence polarization system for rapid COVID-19 diagnosis

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this